Studies revealed the presence of a serologic window wherein serological EBV-VCA IgA antibody levels are elevated and sustained which precedes the clinical onset of NPC, suggesting EBV-VCA IgA as an early marker of NPC (Ji et al., 2007). Here, CD79A is linked to nasopharyngeal carcinoma.